Simvastatin Solid Lipid Nanoparticles for Oral Delivery: Formulation Development and In vivo Evaluation

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Drug Delivery

Background:

• Solid lipid nanoparticles (SLNs) are a promising strategy for enhancing oral drug bioavailability.
• Simvastatin, a Biopharmaceutical Class 2 drug, exhibits poor oral bioavailability (5%).

Purpose of the Study:

• To prepare and optimize simvastatin-loaded solid lipid nanoparticles (SLNs) using hot melt emulsification.
• To characterize the optimized SLNs for physical stability and in vivo performance.

Main Methods:

• Simvastatin SLNs were prepared via hot melt emulsification and optimized for lipid/surfactant concentration and drug loading.
• Characterization included entrapment efficiency, particle size analysis, electron microscopy, X-ray diffraction (XRD), and differential scanning calorimetry (DSC).
• Dry adsorbed nanoparticles were prepared for improved stability, and pharmacodynamic studies were conducted.

Main Results:

• Optimized SLNs achieved entrapment efficiencies >96% and particle sizes <200 nm using glyceryl behenate/palmitostearate and Tween 80.
• Electron microscopy confirmed spherical morphology; XRD and DSC indicated amorphization of simvastatin within the lipid matrix.
• Dry adsorbed nanoparticles exhibited good flow and reconstitution properties.

Conclusions:

• Hot melt emulsification is effective for preparing simvastatin SLNs with excellent entrapment and suitable particle size.
• The amorphized state of simvastatin in SLNs contributes to improved bioavailability, as evidenced by enhanced cholesterol reduction.
• Developed SLN formulations offer a viable approach to overcome the oral bioavailability challenges of simvastatin.